Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SAbR For Oligo-Progressive Renal Cell Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03696277
Recruitment Status : Recruiting
First Posted : October 4, 2018
Last Update Posted : March 25, 2019
Sponsor:
Information provided by (Responsible Party):
University of Texas Southwestern Medical Center

Brief Summary:

Metastatic kidney cancer patients on systemic therapy often develop resistance to limited sites that leads to changing of the systemic therapy. Local therapy to the sites of progression may allow patients to continue on the same systemic therapy that is otherwise effective and being tolerated well.

Hypothesis:

Stereotactic ablative radiation (SAbR) can delay the change of systemic therapy with oligoprogressive renal cell cancer (RCC) and improve progression free survival (PFS).

Primary Objectives:

• To evaluate the benefit of SAbR for oligo-progressive mRCC (Metastatic Renal Cell Cancer).

Secondary Objectives:

• To measure the toxicity, safety and tolerance of concurrent systemic therapy and SAbR for mRCC patients and its impact on quality of life.


Condition or disease Intervention/treatment Phase
Oligoprogressive Renal Cell Carcinoma Radiation: Stereotactic ablative body radiation (SABR) Phase 2

Detailed Description:

The study is a prospective phase II, single arm, open label trial evaluating Stereotactic Ablative Radiation Therapy (SAbR) for patients with oligo-progressive RCC (Renal Cell Cancer).

Problem Statements:

  • Can local therapy (SAbR) for oligoprogression delay the change of systemic therapy if progression is minimal to the progressive sites?
  • Safely delaying the change of systemic therapy can have significant quality of life benefits for patients with oligo-progressive RCC.
  • Can SAbR potentially improve progression free survival in oligoprogressive RCC patients?

Primary Endpoint:

• Time to change of systemic therapy.

Secondary Endpoint:

  • To measure the toxicity, safety and tolerance.
  • To evaluate the progression free survival (PFS) on subsequent systemic therapy after progression on SAbR.
  • To measure the impact on health-related quality of life (HRQOL).
  • To evaluate local control of SAbR for RCC

Sample Size: 20 Patients

Statistical Analysis: Time to event will be estimated using the Kaplan-Meier approach along with the 95% confidence interval.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Stereotactic Ablative Radiation Therapy (SAbR) for Patients With Oligo-progressive Renal Cell Cancer (RCC).
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : October 1, 2020
Estimated Study Completion Date : October 1, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Stereotactic ablative body radiation (SABR)
SAbR will be used to treat all sites of measurable metastases. New sites of metastasis will be treated if deemed appropriate by both medical and radiation oncologists with SAbR.
Radiation: Stereotactic ablative body radiation (SABR)
SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.




Primary Outcome Measures :
  1. Time to change of systemic therapy [ Time Frame: 2 Years ]
    SAbR for oligo-progression will be measured to delay the change of systemic therapy.


Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: 6 years ]
    Progression-Free Survival on systemic therapy started (PFS-ST) after progression on SAbR with existing or new progression at >3 or >30% of all lesions.

  2. Acute & Delayed Toxicity [ Time Frame: 6 Years ]
    Severity or Toxicity will be assessed according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0. The consequences of toxicity should all be graded 1-5 according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.

  3. Local Control [ Time Frame: 6 Years ]
    Radiographic progression with >20% increase in the longest diameter of the treated lesions.

  4. Health-related quality of life (HRQOL) [ Time Frame: 6 Years ]
    HRQOL will be measured using FACT-G.

  5. Health-related quality of life (HRQOL) [ Time Frame: 6 years ]
    HRQOL will be measured using EQ-5D-5L.

  6. Quality of life (QOL) [ Time Frame: 6 years ]
    HRQOL will be measured using FKSI.

  7. Quality of life with cost involved [ Time Frame: 6 years ]
    QOL will be measured using Cost & Convenience Questionnaire.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metastatic renal cell carcinoma with systemic therapy (oligo-progression defined as ≤3 sites of metastasis).
  • Radio-graphic evidence of metastatic disease.

Exclusion Criteria:

  • Subjects with ≥3 unfavorable prognostic factors defined by IMDC (International Metastatic Renal Cell Carcinoma).
  • Subjects with history of or new brain metastasis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03696277


Contacts
Layout table for location contacts
Contact: Raquibul Hannan, MD, PhD 214-645-7696 Raquibul.Hannan@UTSouthwestern.edu
Contact: Samantha Mannala 2146481873 Samantha.Mannala@UTSouthwestern.edu

Locations
Layout table for location information
United States, Texas
University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Neil B Desai, MD    214-645-8302    Neil.Desai@UTSouthwestern.edu   
Contact: Samantha Mannala    2146481873    Samantha.Mannala@UTSouthwestern.edu   
Principal Investigator: Neil Desai, MD         
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Raquibul Hannan, MD, PhD University of Texas

Layout table for additonal information
Responsible Party: University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT03696277     History of Changes
Other Study ID Numbers: STU 052018-001
First Posted: October 4, 2018    Key Record Dates
Last Update Posted: March 25, 2019
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Texas Southwestern Medical Center:
Stereotactic, Radiotherapy,
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Kidney Neoplasms
Kidney Diseases
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urologic Diseases